Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $23.40.

Several equities analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a research report on Friday, November 22nd. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th.

Insider Transactions at Neumora Therapeutics

In other news, Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares of the company’s stock, valued at approximately $342,303. This trade represents a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares of the company’s stock, valued at $4,847,719.66. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,400 shares of company stock valued at $686,361. 26.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Amalgamated Bank raised its stake in shares of Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after acquiring an additional 2,402 shares during the last quarter. Quarry LP bought a new position in Neumora Therapeutics in the 2nd quarter valued at $98,000. SkyOak Wealth LLC acquired a new stake in Neumora Therapeutics in the second quarter worth about $147,000. Principal Financial Group Inc. acquired a new position in Neumora Therapeutics in the second quarter valued at approximately $166,000. Finally, Intech Investment Management LLC acquired a new position in shares of Neumora Therapeutics in the 3rd quarter valued at $175,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Price Performance

Shares of NASDAQ NMRA opened at $10.32 on Friday. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00. The business’s 50-day moving average price is $12.03 and its two-hundred day moving average price is $11.51. The company has a market capitalization of $1.67 billion, a P/E ratio of -5.52 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter in the previous year, the business posted ($1.14) EPS. On average, equities analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.